Expression of matrix metalloproteinases in diffuse gliomas: diagnostic value

Authors

  • T. V. Shynkarenko State Establishment "Dnipropetrovsk Medical Academy of Health Ministry of Ukraine", Dnipro, Ukraine,

DOI:

https://doi.org/10.14739/2310-1237.2017.2.109293

Keywords:

diffuse glioma, immunohistochemistry, diagnostic tests, MMP-3, MMP-9

Abstract

Diffuse gliomas are malignant tumors with high invasiveness, last is provided by the synthesis of proteases, in particular matrix metalloproteinases (MMPs). Expression of metalloproteinases has been repeatedly documented in different forms of diffuse gliomas, but the differential diagnostic possibilities of its usage need additional research.

The aim of the work was to determine the diagnostic role of MMP-3 and MMP-9 expression in brain diffuse gliomas of different histological types and malignancy grades.

Materials and methods. Histological and immunohistochemical examination of diffuse astrocytic and oligodendroglial gliomas (Grade II-IV) was performed (52 samples). The average age of the patients was 43.13 years (age range was 22-73 years), the male: female ratio was 1.08:1.

Results. The intensity of MMP-3 and MMP-9 expression and localization of preserved proteins are similar in diffuse gliomas (however, expression levels coincide in 76.9% of tumors). Predominantly cytoplasmic expression is showed by tumor cells, as well as vascular endothelium. The high level (++) expression of MMP-3 is characteristic for 80.8% glioblastomas (Grade IV WHO), 57.1% of the Grade III tumors, and only among 14.3% of diffuse astrocytes and oligodendrogliomas (p<0.01). The proportion of glioblastomas with high level expression of MMP-9 reaches 75%; the similar expression level of MMP-9 is recorded in Grade II-III diffuse gliomas (in 42.9% and 37.7% of tumors, respectively), p<0.05. The high level expression of MMPs is more frequent in astrocytic tumors than in oligodendrogliomas, but statistically significant difference is not observed (p>0.05). Expression of MMPs depended on proliferative tumor activity and patient's age (p<0.05). There was no statistically significant difference between MMPs expression in women and men.

Conclusions. The expression of MMP-3 and -9 is similar by pattern and intensity in diffuse gliomas of the brain. The intensity of MMPs expression depends on the malignancy grade and Grade-dependent features of diffuse glial tumors.

References

Claes, A., Idema, A. J., & Wesseling, P. (2007). Diffuse glioma growth: a guerilla war. Acta neuropathologica, 114(5), 443-458. doi: 10.1007/s00401-007-0293-7.

Cavenee, W. K., Leung, S. Y., Hawkins, C., Van Meir, E. G., Burger, P. C., & Tabori, U. (2016). WHO Classification of Tumours of the Central Nervous System, Revised. Lyon: IARC. ISBN 978-92-832-4492-9.

Paw, I., Carpenter, R. C., Watabe, K., Debinski, W., & Lo, H. W. (2015). Mechanisms regulating glioma invasion. Cancer letters, 362(1), 1-7. doi: 10.1016/j.canlet.2015.03.015.

Turner, S. G., Ahmad, M., & Toms, S. A. (2016). Mechanisms of Glioma Cell Invasion. In Neurooncology-Newer Developments. InTech. doi: 10.5772/63126.

Mawrin, C., & Seidenbecher, C. (2014). Glioma and Extracellular Matrix. In Glioma Cell Biology (pp. 271-292). Springer Vienna. doi: 10.1007/978-3-7091-1431-5_10.

Sternlicht, M. D., & Werb, Z. (2001). How matrix metalloproteinases regulate cell behavior. Annual review of cell and developmental biology, 17(1), 463-516. doi: 10.1016/j.matbio.2015.01.022.

Gaffney, J., Solomonov, I., Zehorai, E., & Sagi, I. (2015). Multilevel regulation of matrix metalloproteinases in tissue homeostasis indicates their molecular specificity in vivo. Matrix Biology, 44, 191-199. doi: 10.1016/j.matbio.2015.01.012.

Jabłońska-Trypuć, A., Matejczyk, M., & Rosochacki, S. (2016). Matrix metalloproteinases (MMPs), the main extracellular matrix (ECM) enzymes in collagen degradation, as a target for anticancer drugs. Journal of enzyme inhibition and medicinal chemistry, 31(sup1), 177-183. doi: 10.3109/14756366.2016.1161620.

Yang, X., Lv, S., Liu, Y., Li, D., Shi, R., Tang, Z. et al. (2015). The clinical utility of matrix metalloproteinase 9 in evaluating pathological grade and prognosis of glioma patients: a meta-analysis. Molecular neurobiology,52(1), 38-44. doi: 10.1007/s12035-014-8850-2.

Xue, Q., Cao, L., Chen, X. Y., Zhao, J., Gao, L., Li, S. Z., & Fei, Z. (2017). High expression of MMP9 in glioma affects cell proliferation and is associated with patient survival rates. Oncology Letters, 13(3), 1325-1330. doi:10.3892/ol.2017.5567.

Thorns, V., Walter, G. F., & Thorns, C. (2003). Expression of MMP-2, MMP-7, MMP-9, MMP-10 and MMP-11 in human astrocytic and oligodendroglial gliomas. Anticancer research, 23(5A), 3937-3944.

Kunishio, K., Okada, M., Matsumoto, Y., & Nagao, S. (2003). Matrix metalloproteinase-2 and-9 expression in astrocytic tumors. Brain tumor pathology, 20(2), 39-45. doi: 10.1007/s10014-003-0140-9.

Poslavska, OV (2015) Metodologhija vykorystannja proghramnogho zabezpechennja dlja analizu cyfrovykh mikrofotoghrafij na bazi kursu patomorfologhiji z metoju pidvyshhennja profesijnogho rivnja studentiv i naukovciv [Methodology for the use of software for the analysis of digital micrographs on the base of pathomorphology course in order to increase the professional level of students and scientists]. Morphologia, 9(3):122-6. [in Ukrainian].

Shpon‘ka IS, Shynkarenko TV, Poslavska OV. (2016) Kharakterystyka ta analiz ki-67-imunoreaktyvnosti v astrocytomakh gholovnogho mozku [Characterization and analysis of Ki-67-immunoreactivity in brain astrocytoma]. Morphologia, 10(1):96-101. [in Ukrainian].

Antomonov M. (2006) Matematicheskaja obrabotka i analiz mediko-biologicheskih dannyh [Mathematical processing and analysis of medical and biological data.] Kyiv: FMD. 558. [in Russian].

How to Cite

1.
Shynkarenko TV. Expression of matrix metalloproteinases in diffuse gliomas: diagnostic value. Pathologia [Internet]. 2017Sep.27 [cited 2024Mar.28];(2). Available from: http://pat.zsmu.edu.ua/article/view/109293

Issue

Section

Original research